title: A variety of clinical applicabilities of immobilized dextran sulphate as lipoprotein adsorbent and avoidance of anaphylactoid (anion-blood contact) reaction in its use.
abstract: Dyslipidemia including hyper-LDL(low density lipoprotein) cholesterol which is very often refractory to dietary/medical treatments is known to be a risk factor of many arteriosclerotic lesions. An extracorporeal procedure of plasma adsorption, LDL adsorption, utilizing dextran sulphate as a ligand immobilized on cellulose gel beads has been clinically applied in a variety of dyslipidemic conditions as listed below. Its usefulness in secure reduction of the serum LDL level and consequent symptomatic improvements has been confirmed. Familial hypercholesterolemia(FH): A regular repetition of the LDL adsorption ameliorates hyper-LDL cholesterolemia as resulting in regression of the multiple stenoses in the coronary arteries. Focal glomerulosclerosis(FGS): A seesion of the LDL adsorption improves kidney function and reduces a urinary protein excretion in FGS patients with dyslipidemia. Arteriosclerosis obliterans(ASO): More than 60 ASO patients with dyslipidemia have been treated by the LDL adsorption in our center. In over 80% of the patients, marked improvement in clinical symptoms such as leg pain/intermittent claudication has been brought out. Hemodialysis-relevant dyslipidemia(HDDL): HDDL which develops in the long-term HD patients has been treated. Transplantation-relevant dyslipidemia(TXDL): TXDL with deterioration of the transplanted kideny function has been treated by the LDL adsorption. Kidney function improves. Anaphylactoid reaction which is tentatively explained as a result of release of bradykinin in contact of blood with polyanionic material of the adsorbent, dextran sulphate, develops, in particular, while an angiotensin-converting enzyme inhibitor is administered as a depressant. However, it can be avoided in a use of nafmostat mesilate, a protease inhibitor, as an anticoagulant.
authors.affiliation: Kidney Center, Tokyo Women's Medical College, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Agishi
authors.forename: Y
authors.initials: Y
authors.lastname: Sato
authors.forename: S
authors.initials: S
authors.lastname: Nakasato
authors.forename: C
authors.initials: C
authors.lastname: Matsuzawa
authors.forename: T
authors.initials: T
authors.lastname: Sanaka
authors.forename: K
authors.initials: K
authors.lastname: Ota
mesh_terms: D000327:Adsorption; D000707:Anaphylaxis / Q000139:chemically induced / Q000517:prevention & control*; D000838:Anions / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood*; D016264:Dextran Sulfate / Q000627:therapeutic use*; D005112:Extracorporeal Circulation; D006801:Humans; D006949:Hyperlipidemias / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000838:Anions; D008078:Cholesterol, LDL; D016264:Dextran Sulfate